bioMerieux (GB:0RUG)
LSE:0RUG
UK Market
GB:0RUGbioMerieux
€94.96
€0.63 (0.67%)

bioMerieux Stock Analysis & Ratings

bioMerieux Stock Analysis Overview

Smart Score
N/A
Not Ranked
1
2
3
4
5
6
7
8
9
10
Learn more about TipRanks Smart Score
CONSENSUS
Moderate Buy
Average Price Target : €112.00
SENTIMENT
N/A
Currently Not Enough Data Available

HEDGE FUND ACTIVITY

TREND
N/A
Currently Not Enough Data Available
TREND
N/A
Currently Not Enough Data Available

TIPRANKS INVESTORS

SENTIMENT
N/A
Currently Not Enough Data Available
LAST 7 DAYS
N/A
Currently Not Enough Data Available

TECHNICALS

SMA
Negative
20 days / 200 days
MOMENTUM
-28.40%
12 Months Change

FUNDAMENTALS

RETURN ON EQUITY
17.45%
Trailing 12 Months
ASSET GROWTH
3.86%
Trailing 12 Months
This stock does not have enough of the key information we need to rate it accurately. Smart Score is calculated for stocks traded in Nasdaq, NYSE, TSE and LSE with a market cap above $30M and average 3 months trading volume above $30K.

Stock Chart

GB:0RUG

GB:0RUG Stock Stats

Previous Close€94.33
Open€94.87
Bid0 x 0
Ask0 x 0
Today’s Range€93.94 - €95.58
52-Week Range€74.97 - €144.85
Volume61.59K
Average Volume22.99K
Market Cap€11.19B
Beta-0.12
P/E Ratio27.7
EPS3.41
Earnings DateSep 01, 2021
Dividend & Yield0.19 (0.85%)
Ex-Dividend DateJun 04, 2021

Company Description

bioMerieux

BioMerieux designs, develops, and manufactures a broad portfolio of in vitro diagnostics for detecting disease-causing pathogens and contamination. The company operates in four segments: molecular biology (about 38% of sales), microbiology (about 32%), immunoassays (about 15%), and industrial applications (about 15%). Europe, the Middle East, and Africa accounts for the largest portion of the firm's revenue (38%), followed by North America (38%), Asia-Pacific (17%), and Latin America (7%). BioMerieux is headquartered in Marcy-l'Etoile, France.
Sector
Healthcare
Industry
Medical Diagnostics & Research
CEO
N/A
Employees
12,624
Address
Marcy l'Etoile, Lyon, 69280, FR

Financials


P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

GB:0RUG FAQ

What was bioMerieux’s price range in the past 12 months?
bioMerieux lowest stock price was €74.97 and its highest was €144.85 in the past 12 months.
    What is bioMerieux’s market cap?
    bioMerieux’s market cap is €11.19B.
      What is bioMerieux’s price target?
      The average price target for bioMerieux is €112.00. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is €129.00 ,the lowest forecast is €95.00. The average price target represents 17.94% Increase from the current price of €94.96.
        What do analysts say about bioMerieux?
        bioMerieux’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.
          When is bioMerieux’s upcoming earnings report date?
          bioMerieux’s upcoming earnings report date is Sep 01, 2021 which is next month.
            How were bioMerieux’s earnings last quarter?
            bioMerieux released its earnings results on Feb 24, 2021. The company reported €1.959 earnings per share for the quarter, beating the consensus estimate of N/A by €1.959.
              Is bioMerieux overvalued?
              According to Wall Street analysts bioMerieux’s price is currently Undervalued.
                Does bioMerieux pay dividends?
                bioMerieux pays a Annually dividend of €0.62 which represents an annual dividend yield of 0.85%. bioMerieux’s last Annually dividend payment was on Jun 08, 2021. bioMerieux’s upcoming ex-dividend date is Jun 04, 2021
                  What is bioMerieux’s EPS estimate?
                  bioMerieux’s EPS estimate for its next earnings report is not yet available.
                  How many shares outstanding does bioMerieux have?
                  bioMerieux has 117,870,000 shares outstanding.
                    What happened to bioMerieux’s price movement after its last earnings report?
                    bioMerieux reported an EPS of €1.959 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.544%.
                      Which hedge fund is a major shareholder of bioMerieux?
                      Currently, no hedge funds are holding shares in GB:0RUG

                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis